Results 191 to 200 of about 10,854,095 (294)

Improving phase 2/3 trials with an enhanced 2-in-1 adaptive design. [PDF]

Contemp Clin Trials Commun
Youn A, Yang Y.
europepmc   +1 more source

Two-Stage Adaptive Design for Prognostic Biomarker Signatures with a Survival Endpoint. [PDF]

Stat Biopharm Res, 2022
Dai B, Polley MC.
europepmc   +1 more source

Bridging the gap: a genetically validated avian chorioallantoic membrane platform for investigation of spontaneous circulating tumor cells

Molecular Oncology, EarlyView.
We established the avian chorioallantoic membrane (CAM) assay as a scalable in vivo model for studying circulating tumor cells (CTCs). Human gastrointestinal tumors spontaneously released genetically validated CTCs that were detected across multiple platforms, demonstrating that the CAM model provides an accessible tool for investigating early cancer ...
Dennis Roth, Rui P. L. Neves, Julia Geheb, Christian Ballmeyer, Nathalie Gaßmann, Kiki C. Andree, Monica Sudarsanam, Christiane Driemel, Celine Örencik, Andrè Franken, Eslam Elmaghraby, Sven H. Loosen, Roderburg Christoph, Sebastian Schoelch, Hans Neubauer, Wolfram T. Knoefel, Nikolas H. Stoecklein, Georg Fluegen   +17 more
wiley   +1 more source

Adaptive Design with Bayesian Informed Interim Decisions: Application To a Randomized Trial of Mechanical Circulatory Support. [PDF]

Ther Innov Regul Sci
Mukherjee R, Muehlemann N, Gao Y, Stone GW, Mehta C.   +4 more
europepmc   +1 more source

Extracellular matrix remodeling and immune reprogramming drive residual tumor progression of liver cancer after incomplete microwave ablation

Molecular Oncology, EarlyView.
Incomplete microwave ablation (iMWA) of liver cancer triggers a biphasic progression in residual tumors. At Day 3, the microenvironment is characterized by acute inflammatory responses and extracellular matrix (ECM) remodeling. By Day 14, a profound shift occurs toward oncogenic signal transduction and immunosuppression, marked by macrophage ...
Yu Liu, Yubei He, Nikolaus Berndt, Michael Mülleder, Kathrin Textoris‐Taube, Jing Guo, Matthias Stechele, Justus Ramtke, Shraga Nahum Goldberg, Lynn Jeanette Savic   +9 more
wiley   +1 more source

Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics. [PDF]

Emerg Infect Dis
Bourner J, Vaillant M, Abdel Salam AP, Jaspard M, Fritzell C, Jacob ST, Fletcher TE, Ramharter M, Ajayi N, Okogbenin S, Erameh C, Grant D, Samuels R, Ayodeji OO, Sprecher A, Gonçalves BP, Edwards T, Olliaro P, WALC Work Package 2 Working Group.   +18 more
europepmc   +1 more source

Unique circulating miRNAome signatures captured with distinct molecular states in Lynch syndrome and sporadic colorectal cancer

Molecular Oncology, EarlyView.
Circulating microRNA profiles distinguish nonmalignant Lynch syndrome from cancer‐associated Lynch syndrome, sporadic colorectal cancer, and healthy controls. Age‐stratified analysis reveals disease‐specific regulatory states, and a six‐miRNA panel shows concordant separation in an independent colorectal tissue cohort.
Ramadhani Salum Chambuso, Md Shohel Ul Islam, Rosa M Xicola, Raj Ramesar, Xavier Llor, Sinclair Steele   +5 more
wiley   +1 more source

A Novel Adaptive Design Approach for Early-Phase Clinical Trials to Optimize Vaccine Dosage. [PDF]

China CDC Wkly
Tong X, You D, Shao F, Lu M, Zhao Y.
europepmc   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Control of Unconditional Type I Error in Clinical Trials With External Control Borrowing-A Two-Stage Adaptive Design Perspective. [PDF]

Pharm Stat
Gao P, Ni X, Li J, Chu R.
europepmc   +1 more source